<SEC-DOCUMENT>0001213900-26-004507.txt : 20260115
<SEC-HEADER>0001213900-26-004507.hdr.sgml : 20260115
<ACCEPTANCE-DATETIME>20260115091510
ACCESSION NUMBER:		0001213900-26-004507
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260115
FILED AS OF DATE:		20260115
DATE AS OF CHANGE:		20260115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ASCENTAGE PHARMA GROUP INTERNATIONAL
		CENTRAL INDEX KEY:			0002023311
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42484
		FILM NUMBER:		26534844

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		68 XINQING ROAD
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			SUZHOU , JIANGSU
		PROVINCE COUNTRY:   	F4
		BUSINESS PHONE:		86 512 8555 7777

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		68 XINQING ROAD
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			SUZHOU , JIANGSU
		PROVINCE COUNTRY:   	F4
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0273032-6k_ascentage.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Washington,
D.C. 20549 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Form
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>under the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of <B>January 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-42484</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASCENTAGE PHARMA GROUP INTERNATIONAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Translation of Registrant&rsquo;s name into
English)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>68 Xinqing Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suzhou Industrial Park</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suzhou, Jiangsu</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>China</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 20-F &#9746; Form 40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 53.3pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 53.3pt 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 53.3pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 14, 2026, Ascentage
Pharma Group International issued a press releases entitled &ldquo;Ascentage Pharma Outlined its Global Innovation Strategy During Presentation
at 44th Annual J.P. Morgan Healthcare Conference&rdquo;. A copy of the press release is furnished as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit Title</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 9%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 90%">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="ea027303201ex99-1_ascentage.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated January 14, 2026</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASCENTAGE PHARMA GROUP INTERNATIONAL</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: January 15, 2026</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Dajun Yang</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dajun Yang</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea027303201ex99-1_ascentage.htm
<DESCRIPTION>PRESS RELEASE DATED JANUARY 14, 2026
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 50.95pt; width: 135.35pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ascentage
Pharma Outlined its Global Innovation Strategy During Presentation at 44<SUP>th</SUP> Annual J.P. Morgan Healthcare Conference</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Two
                                            commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth
                                            with strong China market presence</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Next-generation
                                            BTK protein degrader APG-3288 receives IND clearance from the U.S. FDA&#65292;propelling
                                            expansion of global innovative pipeline</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Multiple
                                            global registrational Phase III trials are progressing rapidly</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ROCKVILLE,
Md. and SUZHOU, China, January 14, 2026</B>&mdash;Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial
stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies
to address unmet medical needs in cancer, announced that its Chairman and CEO, Dajun Yang, M.D., Ph.D., presented at the 44th Annual
J.P. Morgan Healthcare Conference. In the corporate presentation, Dr. Yang provided an overview of milestone achievements in 2025 and
outlined the Company&rsquo;s global innovation strategy for 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Yang said, &ldquo;The annual J.P. Morgan Healthcare Conference provides an important platform for us to engage with peers from around
the world and showcase our strategy and progress. For Ascentage Pharma, 2025 has been a critical year in which we accelerated our global
expansion, advancing product commercialization, global clinical development, and pipeline innovation. To date, we have built a powerful
engine for innovation in hematologic malignancies and solid tumors, harnessing a diverse range of mechanisms and synergies between core
components that include our commercialized products, late-stage programs in solid tumors, as well as our early-stage innovative therapies
that utilize our cutting-edge protein degradation technology. This multi-faceted global portfolio of products and clinical programs has
well positioned Ascentage Pharma for future challenges and laid a solid foundation for sustained growth. Entering 2026, Ascentage Pharma
is opening a new chapter on its global innovation strategy. We remain steadfastly committed to our mission of addressing unmet clinical
needs around the world, and accelerate the development of our promising innovative therapeutics for the benefit of patients worldwide.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dual-Engine
Driven by Two Core Products: Building a Global Hematologic Malignancy Treatment Landscape</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s two core products, the third-generation BCR-ABL inhibitor Olverembatinib and the Bcl-2 inhibitor Lisaftoclax, both achieved
significant progress in 2025 and represent main growth drivers for 2026. Together, they generate powerful &ldquo;dual-engine&rdquo; effects
that will drive the Company&rsquo;s future growth and support the development of a global portfolio of innovative therapies covering
a broad range of hematologic malignancies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Yang continued, &ldquo;In the past year, Ascentage Pharma has made progress across multiple clinical studies on its key drug candidates
globally, and presented data from these studies at prestigious international academic congresses. These data underscored the Company&rsquo;s
potential in delivering clinical breakthroughs for challenging hematologic malignancies and the global competitiveness of its products.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Developing
the Next-Generation BTK Degrader: Propelling Strategic Expansion of Global Innovative Pipeline</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Achieving
breakthroughs in translational medicine and the development of a diverse pipeline, Ascentage Pharma has received an investigational new
drug (IND) clearance from the U.S. FDA for APG-3288, the first novel, highly potent and selective BTK degrader developed utilizing Ascentage
Pharma&rsquo;s proprietary proteolysis-targeting chimera (PROTAC) technology platform. This clearance initiates Ascentage Pharma&rsquo;s
clinical development in the field of targeted degradation and lays a strong foundation for future exploration of the combinatory potential
between APG-3288 and the Company&rsquo;s existing proprietary small-molecule agents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adding
to the dual-engine effect generated by Olverembatinib and Lisaftoclax, other assets in the Company&rsquo;s pipeline are also making rapid
progress, forming a portfolio of advancing programs. The Company&rsquo;s other key clinical programs include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APG-5918
(EED inhibitor): Preclinical data have shown therapeutic potential in hematologic malignancies (multiple myeloma and T-cell lymphoma)
and solid tumors (prostate cancer). For non-hematologic indications, the Company is conducting a Phase I study in patients with anemia
in China.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APG-2449
(FAK/ALK/ROS1 inhibitor): Has entered global registrational Phase III studies in non-small cell lung cancer (NSCLC), representing a major
breakthrough in the Company&rsquo;s expansion into solid tumors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alrizomadlin
(APG-115; MDM2-p53 inhibitor): Currently being evaluated in a Phase II study and has shown clinical potential in solid tumors such as
adenoid cystic carcinoma (ACC).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pelcitoclax
(APG-1252; Bcl-2/Bcl-xL inhibitor): Currently being evaluated in a Phase II study, having shown clinical potential in a range of tumor
types including EGFR-mutant NSCLC, relapsed/refractory non-Hodgkin lymphoma, ovarian cancer, and endometrial carcinoma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outlook
for 2026</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the presentation, Dr. Yang touched on a number of potential milestones and catalysts expected in 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
global clinical development: Advance multiple registrational Phase III studies including GLORA, GLORA-4, POLARIS-1, and POLARIS-2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
commercialization: Continued growth in commercial sales, broader patient accessibility and coverage across 1,500 hospitals; Inclusion
in NRDL coverage of Lisaftoclax in China.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
early-stage clinical programs: BTK Protein Degrader APG-3288 global Phase I PK, safety, tolerability, efficacy data, including U.S. and
China; Advancement of EED Inhibitor APG-5918 in oncology and anemia in the U.S. and China.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>*Olverembatinib,
Lisaftoclax, Alrizomadlin, Pelcitoclax, APG-3288, APG-5918, and APG-2449 are currently under investigation and have not yet been approved
by the U.S. FDA.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Ascentage Pharma</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ascentage
Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (&ldquo;Ascentage Pharma&rdquo; or the &ldquo;Company&rdquo;) is a global, commercial
stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies
to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that includes
inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, as well as next-generation kinase inhibitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lead asset, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with
CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant
or intolerant to first and second-generation TKIs. All indications are covered by the China National Reimbursement Drug List (NRDL).
The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of Olverembatinib for CML, as
well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies.
Lisaftoclax is being commercialized in China following National Medical Products Administration (NMPA) approval for the treatment of
adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic
therapy including BTK inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA
study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than
12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed,
elderly and unfit patients with acute myeloid leukemia (AML); and the GLORA-4 study in patients with newly diagnosed higher-risk myelodysplastic
syndrome (HR MDS), a study that was simultaneously cleared by the U.S. FDA, the EMA of the EU, and China CDE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leveraging
its robust R&amp;D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global
partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck,
Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer
Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section
27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other
than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express
Ascentage Pharma&rsquo;s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future
results of operations or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma&rsquo;s filings with the
SEC, including those set forth in the sections titled &ldquo;Risk factors&rdquo; and &ldquo;Special note regarding forward-looking statements
and industry data&rdquo; in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form
20-F filed with the SEC on April 16, 2025, the sections headed &ldquo;Forward-looking Statements&rdquo; and &ldquo;Risk Factors&rdquo;
in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or
The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance
or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking
statements contained in this presentation do not constitute profit forecast by the Company&rsquo;s management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking
statements contained in this press release are based on Ascentage Pharma&rsquo;s current expectations and beliefs concerning future developments
and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update
or revise any forward-looking statements, whether as a result of new information, future events or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contacts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Relations:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stella
Yang</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ascentage
Pharma</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stella.Yang@ascentage.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+1
(301) 792-6286</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephanie
Carrington</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ICR
Healthcare</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AscentageIR@icrhealthcare.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+1
(646) 277-1282</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Media
Relations:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sean
Leous</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ICR
Healthcare</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AscentagePR@icrhealthcare.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+1
(646) 866-4012</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "< 9X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**** "B
MBB@ HHHH ***,XZT %%&X>M&X>M !11N'K1D>M !10"#T-&1ZT %%%&1ZT %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4$X&: 0>AH)&*
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M$-)UK=K:J%_OW;/Q3#T<XQ&;/!Y=#V^82LZE2>L*%^]]'-=M;;),\<U7Q/\
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ML#=GINK]6 VY01^%<N=9AQMD.(A3Q6)FG**DK2=K/]5U/8R'AKPWXAPLY83
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M(]:,@]#0 449HR/6@ HHS10 4444 %%%% !1103CK0 449%&X9ZT %%&X>M
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M_"/XN?#KXX>!;'XD_"[Q3;:OHVI1B2VO+63(]U/H1T(/(-?SI?M<?L:_&O\
M8K\?6_@'XT:7;PSWUL;C3KRSN!)#<Q!L$JW8@]1U%?:__!NE\?=;TOXI>*OV
M>=4U:233-2TW^TM,LV.5BN(SB1ASP"I' [\UT<5<#Y)3R%YKE$VXQL[7O%J]
MM'W1Q\)<?9[4S^.59O'63:VM)2WU7F?KZY..!7A/[7O_  4-_9I_8MTT)\5_
M&'F:Q-'OL_#^G+YMW*.<$H/N*2/O' K>_;7_ &C]/_90_9J\3?&F]DB-QIMD
M4TJWE;_77;_+$@]>><=PIK^<_P")OQ+\>_&[X@ZC\1/B%KEUJVM:Q=&6XN)F
M+L[,>$4=@,X"CH*^?X%X*CQ+.5?$2Y:,'9VWD][7V5NK/J./>.)<+QCAL+'F
MK35U?516U[=6^B/U.U/_ (.3?ALER1HW[.>O-%V:XU&$,?RJM_Q$H>#CP?V<
M=6_\&45?&7A7_@D)^WOXQ^'"_$W2/@Q(MG)#YUO8W%XB7DR$9!6(\\CIS7S?
MKNB:OX9UBZ\.^(-,GL;^RF:&[L[F,I)#(IP58'H0:_3L%P3P#C92IX>TW'>T
MVVO6S/RG&\<>(&"C&IB6X*>UX)+Y:'[=?L0?\%JO _[8OQYL_@9%\(=2T.ZO
M[26:UO);I)$+( 2I Y&1WZ<5]M:_K^B^%](N->\1:M;V-E:QF2XNKJ41QQJ.
MY8\ 5\$_\$<?V#OV3-$^'_AS]LGX;:]K.N:]?6$T7G:G,J+8R'"31>6G!964
MJ&ST)KYF_P""Y7_!0/Q+\2_BS>?LI?#3Q%-;^&?#4WE>(&M9MHU&^'WHVQU2
M,_+MZ;@3Z5^9UN&L#GW%;R_*(RA3C\3E?2SLWKKY)/KY'ZA1XIS'A_A-9AF\
MHU*DW[BBUJFM%IIYM]CZO_:!_P""^?[(_P )M?D\-_#W3-6\<302-'<7.D;(
M[=&']V23 <?3IBN$\&?\'('P,U/6H;'QI\#_ !)I=G+,%FOH;B*80H3]XH#N
M; ["OSJ_8E_8%^./[=?C*Z\/_"ZUAM=-TW;_ &OKVH!A;VF[HO'WW/\ ='..
M?KZQ^V+_ ,$6?VE/V2/AA-\7F\0Z7XLT6Q^;6)-'@D22Q3( D*/RR9/)'3O7
MVLN$O#O!8J.6XBL_;.V\M;O;963?9^1\/'C#Q&QN%EF5"DO8K72.EEOOJTNY
M^T'[.?[4GP/_ &J/!B^._@CXZM=8LP%%Q$C;9[5B,A)8S\R-]?0UZ(A^;D_A
M7\U/['7[6OQ(_8V^-FF_%OX?:I,L,<R1ZYI0D_=:E9[OGB=>A.W)5NJM@CN#
M_1U\-_&^@?$_P-HWQ$\*7JW&EZUIL-]I]PO26&6,.K?B#7YWQIPC/A;&1Y)<
MU*?POKINGYKOU/TO@?C*/%>$DJD>6K#XDMFGLU]WR.@HHHKXH^["BB@G S0!
M&>N:^9_^"CW_  3A\%?\% /!NE6FI>)9M#\0>'3.VAZI%&)$'FJNZ*1>Z,R1
MDXY&WBOIG/?%)@DY-=6!QV+RW%QQ.&ERSCLUZ6^ZVYQ9AE^$S3!RPN*CS0DK
M-?B?&G_!-+_@DEX8_81UZ^^)GB7QS_PDGBR^T]K-9X;?R[:TB+[F\M3\VYL*
M"2>!D#J:^RSP,XYH '6E.>M:9GF>.S?%O$XJ;E-VU=MEMHMD9Y7E6!R7!K#8
M2'+!=/7=Z[L3<>]?.7_!4/\ :LM?V2_V2?$/C*SO5CUS583IGA^+=\SW4H*[
M@.X1<L?937T;N7DDU^'_ /P7B_:SD^-G[34?P1\-:JLV@^ XS%-Y$F4FU!QF
M0G'!V+A1W!+ U[W!.1O/L^ITI+W(^]+T7^;LCY[CK/ED/#U2I%VG/W8^K_R6
MI\+SSSW<\EU=3/))(Y:221BS.Q.22>Y)KZZ_9K\+:AX$^%$>FS7<J'5I%O;R
MWWD*S8^3(Z$A3D9Z9KYQ^"/@:3X@?$.RT:2-FMH7\^\/I&ISCVR>*_4C]D+]
M@WQ?\=YHO$WBR";1_"\.W;(R;9+O_9C!Z+_M?E7B_2BXDS+-*F%X-RB[E/\
M>54ND5I%2?1;O7L>W]%;AO+,KIXOC3.;*$/W=)O=R>LG%=7:RT[L\W^!_P"S
MW\2_V@?$:Z#X"T5GC4C[5J$RE8+=?5F]?8<UG?\ !8?]ACQ-^S3\%O"OCWP;
MXDO[W36N&L_%CK\L?G/S$^!T7@J!W)YK]:_A[\-?!OPL\-6_A+P1H$-C9VZ
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M[<D+^.]'COXO#?AVYU:QMIXPT9N4DBC1F!Z[?-W#_:4'M7[LQQ\8 [U^*/\
MP;MC_C-W6L_]"!=_^E5K7[99(XS7A>*E2I+BAQDW90C9=%?<^@\):=./"JG&
M*NYRN^KML?CY_P '(GP_\*Z#\9OAS\0--TM8=4UW1;^WU.=>/.2VD@,6?<><
M_/<''85\\?\ !&[6[G0?^"BG@&>V)S<7%S;M_N26[H?YU]0?\'+O/C3X1?\
M8.UK_P!#LJ^4?^"19S_P4,^''_85?_T4U?H?#\I5_#-J;O:%3[DW8_->(5&C
MXG+D5O?A][L?N]^U* ?V=/&V1_S+-Y_Z*:OYD>@K^F_]J)'D_9V\:)&A9CX9
MO,!1U_=-7\R'4<5Y7@]_N>*]5^1[/C/_ +[A/\+_ #/Z$O\ @C\/^-<OPQR!
M_P @F?\ ]+)Z^EV*[<DU\'?\$POVY?V3?A3_ ,$]_!.B_$+XXZ'I-YH-C-;Z
MI975P1-!)]HE<#8 6.593D CFOJ3P-^TA\,_C]\#]6^,'P'\7PZUIUO;WD5O
M>6Z,N+B)"2N& .?NG\17Y-GF7XZGFU><Z<E%U)*[32NV[:GZUP_F6 EDU"$*
MB<E33LFF[):Z'R1_P4=_X+8^'_V8_&-U\$_@'H-GXB\462E-6U*ZD/V73I"/
M]6 /]9(.I'0=#7P?X@_X+>?\%"-=OH[T?%"PLQ&VX0V.D1QHW/1AW%?+WC_7
M-7\2^.M:\1:_([7U_JEQ/>-(<MYCR,S9_$U^V_\ P1P_9?\ V:;3]BKPS\0[
M#P'HFL:WX@MWFU_4KRUCN)?.$A'DDL#M"@#Y>,9]Z_7\?E?#/ ^0T:];"JO4
ME9-OJVKO>Z2[)(_',#FG%''7$%6A1Q3HPC=I+2R3M;2S;[GY(_M6?MO_ !W_
M &S+C1[[XZ:GI]Y<:'"\5C-9Z>L#;&Y(;'WN:]S_ ."![L/^"A&FHK<-X6U+
M</\ @"5VO_!P5X?^"?AOXW^$;#X9Z3H=EJ@TB7^W8-(BC1E^<>6)53@''3/.
M*XK_ (()8/\ P4)TWY?^97U+_P! 2O8Q6*PN,\.:U;#T?90<':';7IY/<\/"
MX7%8+Q%I4<15]K-32<N^A][_ /!P';WD_P"P3*]M&S)'XLT]I@J$X&9.?8"O
MR._86G^'=O\ M@_#N;XK) = 7Q/;_;A<#]WG/[O=[>9LK]AO^"QW[7O[._P=
M_9ZU;X'?$W3I-<UKQAILD5CHEG(%DA[K<.W\"JP&.YP17X11.\965"5*L"K*
M>0<UYWAGAJ^(X5KX:<7!3<N65MU)6NO1GJ>)V*P^'XNHXFG)3<%'FC?9Q=[/
MU1_5%:^0ULGV0+Y/ECR]GW=N..G:OP*_X+5S>"IO^"A7C$^"OL_EB&T&H-:X
MV_:_(7SLX_BW9S[US7A7_@JQ^W?X*^'*_##0OCSJ"Z?'#Y5O<2JKW,$?94E(
MW  =/2O(/ G@#XJ_M&?$^W\)^#=*U#Q%XDUR\W-]Z221V;YI9&YPH)R6/ JN
M#^"L9PIF53'8NM'D46E:]K:.[OML'&7'&%XMRZC@<)1DI\R;O:]TK65O4_5[
M_@W9UV^M_P!D[X@2WEQ-);:?XN=H8BQ81J+.)R%';)R>.YK\DOB9K>H>(OB+
MKNNZI=27%U>:O<RS33'+.QD8Y/O7]#7_  3^_9#T[]CC]E[1_@X[Q7&J-"US
MKUY&G$]U+R_U5?NKGH *_ S]JGX1^(/@3^T7XP^%?B:%UNM)UZXC61HROFQE
MRR2#/\+*00>X-9\!YE@L?Q5F5:B_C:<?.*;3:_#[T5Q[E>.RWA/+*59? FI>
M3:32?XG>?LP_\%+?VH_V/_ DWPY^".M:+8Z;<7SW=Q]HT9)I))6 !+,3D\
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M6+Z3;'#;QR7-Q,WX99J_9S_@BC_P3C\9?LH^%=1^-?QGL?LGBKQ1;QQ6^CL
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MAWQ!C:+IU,R<UV?,U\U<][!^(O#^7UE4IY8H/NK7^3:/Z@#@C!KX9_X*Y_\
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M\"_%WQ!X9^,T-Y'XJM=6F&M27S,TLL^\EI=S8+!L[@W<$$5_4#M8#YJ^7/\
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M*.VV)<N?KC%?GQ^V-_P5[\8?$^UNO '[/%I<^']%GC:*ZUJXPMY.I.,)@D1
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MY[TK$ 8Q2+G/2OGV^:5SZ*,>560ZBBB@H**** "BBB@ HHHH **** "BBB@
M_"BBB@ HHHH *.O4444 &/:CWQ110 =>HHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
-** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
